Company intelligence / Profile preview

Ceregene

San Diego, California, United Statesceregene.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Ceregene advanced multiple AAV-based gene therapies into clinical trials for major neurodegenerative diseases. CERE‑120 reached Phase 2 in Parkinson's but did not meet efficacy endpoints versus control, though it was safe and well-tolerated. CERE‑110 for Alzheimer’s entered a multi-center Phase 2 trial with NIH support; early studies showed safety but efficacy was unproven at the time of reporting[6][9]. Other programs remained preclinical or were discontinued.

Therapeutic areas: OphthalmologyNeurologyEndocrinology
Modalities: Gene therapyAAV-based gene therapy
Industry: Biotech

Drug pipeline

1 asset

CERE-130

Discontinued

Partnerships

University of California San Diego/Alzheimer's Disease Cooperative StudyMichael J. Fox Foundation

Beyond the preview

Go deeper on Ceregene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceregene.

Explore the full profile